The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: This study was conducted to identify prognostic factors in patients with papillary thyroid cancer (PTC) at the time of first radioactive iodine (RAI) therapy, and to evaluate the clinical value of the thyroglobulin (Tg) increase after RAI. Methods: Serum Tg was sampled prior to (pre-Tg) and 7 days after RAI (post-Tg) in 680 patients with PTC. Patients were classified into excellent response (ER), biochemical incomplete response (BCIR), structural incomplete response (SIR), and indeterminate response (IR) groups using dynamic risk stratification at 6 to 18 months after RAI therapy. Results: After RAI therapy, 514 patients (75.6%) had an ER, 34 (5.0%) had a BCIR, 13 (2.0%) had an SIR, and 119 (17.5%) had an IR. Pre-Tg level was significantly different among the groups, with the highest level being in the SIR group, followed by the BCIR, IR, and ER groups. However, post-Tg levels were not different among the groups. Post-Tg level increased significantly after RAI therapy compared to the pre-Tg level (mean 13.8 ± 32.2 ng/mL vs. 2.5 ± 8.9 ng/mL). In 422 patients whose pre-Tg level was < 1 ng/mL, 205 had post-Tg levels < 1 ng/mL, while 167 had post-Tg levels of 1 to 10 ng/mL, and 50 had levels > 10 ng/mL. No difference was observed in the response to therapy. Differences in RAI dose and uptake pattern were observed among the three groups. Conclusions: Pre-Tg was useful as a prognostic factor in patients with PTC. In patients with low pre-Tg, increased post-Tg may reflect remnant tissue and does not help predict the prognosis.
Abstract
Background/Aims: This study was conducted to identify prognostic factors in patients with papillary thyroid cancer (PTC) at the time of first radioactive iodine (RAI) therapy, and to evaluate the clinical value of the thyroglobulin (Tg) increase after RAI. Methods: Serum Tg was sampled prior to (pre-Tg) and 7 days after RAI (post-Tg) in 680 patients with PTC. Patients were classified into excellent response (ER), biochemical incomplete response (BCIR), structural incomplete response (SIR), and indeterminate response (IR) groups using dynamic risk stratification at 6 to 18 months after RAI therapy. Results: After RAI therapy, 514 patients (75.6%) had an ER, 34 (5.0%) had a BCIR, 13 (2.0%) had an SIR, and 119 (17.5%) had an IR. Pre-Tg level was significantly different among the groups, with the highest level being in the SIR group, followed by the BCIR, IR, and ER groups. However, post-Tg levels were not different among the groups. Post-Tg level increased significantly after RAI therapy compared to the pre-Tg level (mean 13.8 ± 32.2 ng/mL vs. 2.5 ± 8.9 ng/mL). In 422 patients whose pre-Tg level was < 1 ng/mL, 205 had post-Tg levels < 1 ng/mL, while 167 had post-Tg levels of 1 to 10 ng/mL, and 50 had levels > 10 ng/mL. No difference was observed in the response to therapy. Differences in RAI dose and uptake pattern were observed among the three groups. Conclusions: Pre-Tg was useful as a prognostic factor in patients with PTC. In patients with low pre-Tg, increased post-Tg may reflect remnant tissue and does not help predict the prognosis.
참고문헌 (20)
- Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26, pp.1~133 (2016)
- 박희정, "Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma", Nuclear Medicine and Molecular Imaging, 48(4), pp.255~261 (2014), 대한핵의학회
- Lin Y, "Predictive value of preablation stimulated thyroglobulin and thyroglobulin", thyroid-stimulating hormone ratio in differentiated thyroid cancer, 2011, pp.36, 1102~1105
- Lee JI, "Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma", Surgery, 153, pp.828~835 (2013)
- Kim TY, "Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma", J Clin Endocrinol Metab, 90, pp.1440~1445 (2005)
- Mazzaferri EL, "A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma", J Clin Endocrinol Metab, 88, pp.1433~1441 (2003)
- 정금철, "Iodine Uptake Patterns on Post-ablation Whole Body Scans are Related to Elevated Serum Thyroglobulin Levels After Radioactive Iodine Therapy in Patients with Papillary Thyroid Carcinoma", Nuclear Medicine and Molecular Imaging, 50(4), pp.329~336 (2016), 대한핵의학회
- Edge S, "AJCC Cancer Staging Manual", pp.59~64 (2010), Springer-Verlag
- Giovanella L, "Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma", Head Neck, 32, pp.568~571 (2010)
- Lee SJ, "The role of preoperative and postoperative thyroglobulin measurements in the detection of well differentiated thyroid carcinomas recurrence", J Korean Soc Endocrinol, 15, pp.542~553 (2000)
- Toubeau M, "Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer", J Nucl Med, 45, pp.988~994 (2004)
- Zhao T, "Value of serial preablative thyroglobulin measurements : can we address the impact of thyroid remnants", Nucl Med Commun, 37, pp.632~639 (2016)
- Nascimento C, "Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level", Endocr Relat Cancer, 18, pp.R29~R40 (2011)
- Rosario PW, "Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence", Thyroid, 21, pp.49~53 (2011)
- Kim YI, "Serum thyroglobulin level after radioiodine therapy (day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer", Ann Nucl Med, 29, pp.184~189 (2015)
- Bernier MO, "Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 32, pp.1418~1421 (2005)
- Webb RC, "The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients", J Clin Endocrinol Metab, 97, pp.2754~2763 (2012)
- Muratet JP, "Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma", J Nucl Med, 38, pp.1362~1368 (1997)
- Mostafa M, "Variants and pitfalls on radioiodine scans in pediatric patients with differentiated thyroid carcinoma", Pediatr Radiol, 46, pp.1579~1589 (2016)
- Lee M, "Frequent visualization of thyroglossal duct remnant on post-ablation 131I-SPECT", CT and its clinical implications, 2015, pp.70, 638~643